Botanix revenue surges but losses deepen and asset base thins

Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an update.

Botanix Pharmaceuticals reported a sharp increase in revenue from ordinary activities to $16.5 million for the half year ended 31 December 2025, up from just $34,673 a year earlier, but the business remains loss-making with a pre‑tax and after‑tax loss of $33.2 million, slightly higher than the prior corresponding period. Overall comprehensive loss widened to $33.7 million as other comprehensive income swung negative, while net tangible assets per share fell from 2.71 cents to 1.39 cents and the company again declared no interim or final dividend, underscoring ongoing balance sheet pressure and a continued focus on reinvestment over shareholder payouts.

Basic and diluted earnings per share from continuing operations were a loss of 1.69 cents, marginally improved from a 1.70 cent loss in the prior period, indicating that the substantial revenue growth has yet to translate into profitability. The deterioration in net tangible assets per share and absence of dividends suggest investors face continued near‑term dilution and limited income returns as Botanix prioritises funding operations and advancing its pharmaceutical portfolio.

The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.

More about Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited operates in the pharmaceutical and biotechnology sector, focusing on the development and commercialisation of therapeutic products. The company’s activities centre on bringing new treatments to market, positioning it within the broader healthcare and life sciences industry.

Average Trading Volume: 7,962,863

Technical Sentiment Signal: Sell

Current Market Cap: A$124.2M

For a thorough assessment of BOT stock, go to TipRanks’ Stock Analysis page.